000

Closing gaps in malaria policies: Regional and inter-country coordination

Reunión Regional de PAVE 2023

Roberto Montoya PAHO






Malaria cases and deaths, the Americas 2010-2022

480,000 cases in 2015 480,000 cases in 2022 *P. Vivax 74 % P. falciparum 26%*


169 deaths in 2015 92 deaths in 2022

2015-2022 0% reduction in cases 45% reduction in deaths





Plan of Action for malaria Elimination, 2021 - 2025



From control to elimination: key changes

- 1. Consolidate malaria-free microterritories (microplanning)
- 2. Expanding access to diagnosis and treatment
- 3. More effective strategies to prevent relapses in *P. vivax*
- 4. Reactive interventions and chemoprevention
- 5. Improve coverage with LLIN

Closing gaps in malaria policies: Regional and inter-country coordination



Sentinel surveillance to guide expansion of diagnosis and treatment

Changes towards elimination

- 1. Consolidate malaria-free microterritories (microplanning)
- 2. Expanding access to diagnosis and treatment
- 3. More effective strategies to prevent relapses in P. vivax
- 4. Reactive interventions and chemoprevention
- 5. Improve coverage with LLIN


Issues to be addressed with sentinel surveillance

- RDT performance in low transmission/low parasitemia situations
- Implications of low transmission on diagnosis and treatment strategy
- Importance of asymptomatic malaria
- Oligosymptomatic /atypical manifestations in *P. falciparum and P. vivax*
- Implications of low transmission on clinical manifestations
- Implications of low transmission on parasitological parameters



#UniversalHealt

- Epidemiological and operational justifications for chemoprevention interventions
- Molecular surveillance of antimalarial drug resistance in P. falciparum
- Surveillance of therapeutic failure in P. Falciparum
- Molecular epidemiology (parasite populations dynamics)
- HPRP2d prevalence in P. falciparum
- G6PDd prevalence in *P. vivax* afected populations



Radical cure policies – status and gaps in policies

Topic	Status and gaps in policies
Epidemiological importance of relapses	 Only some contries using operational definitions of relapses No routine analysis on the importance of relapses No characterization of the role of relapses in specific populations
Selection of therapeutic schemes	 Assumption that there is not tropical strains tolerant to PQ Several countries already using 7 days scheme (3,5 mg/kg) Tafenoquine: pilot implementation
Safety G6PD testing	 No use of G6PD testing in the Región G6PD test. Pilot experiences / operational studies in some countries (PAVE) No G6PDd testing context: Assumption of generalized low prevalence of G6PDd No understanding of heterogeneity of G6PDd and associated risks Pharmacovigilance and patient counseling not systematically implemented No individual risk benefit analysis systematically implemented
Prescription, use and adherence	 Direct observed treatment in some countries / assumption that DOT is posible Absense of alternatives strategies to improve adherence or if existed, no systematically implemented Use of envelopes, other tools and SBC strategies only in some countries Need of more innovation and tools to improve adherence
Other interventions	No other interventions on relapses being implemented with specific populations (seasonal malaria)

Changes towards elimination

- 1. Consolidate malaria-free microterritories (microplanning)
- 2. Expanding access to diagnosis and treatment
- 3. More effective strategies to prevent relapses in P. vivax
- 4. Reactive interventions and chemoprevention
- 5. Improve coverage with LLIN




#UniversalHealth

Interventions in the final phase of elimination and prevention of re-establishment

Changes towards elimination

- 1. Consolidate malaria-free microterritories (microplanning)
- 2. Expanding access to diagnosis and treatment
- 3. More effective strategies to prevent relapses in P. vivax
- 4. Reactive interventions and chemoprevention
- 5. Improve coverage with LLIN





Mass, Targeted and Reactive Strategies for Elimination



#UniversalHealth





Mass strategies

Targeted strategies

Reactive strategies

Baja certeza	
Certeza muy baja	
Certeza muy baja	
Certeza moderada	
Certeza muy baja	

Certeza muy baja

Certeza muy baja

Certeza muy baja

Certeza muy baja

Baja certeza Certeza muy baja Baja certeza



Closing gaps in malaria policies

Changes towards elimination

- 1. Consolidate malaria-free microterritories (microplanning)
- 2. Expanding access to diagnosis and treatment
- 3. More effective strategies to prevent relapses in P. vivax
- 4. Reactive interventions and chemoprevention
- 5. Improve coverage with LLIN


Country process

- 1. Identify policy gaps in each country
- 2. Address gaps in evidence to guide policies
- **3. Design, validate,** pilot new policies
- **4. Implement new policies** and strategies



Global (WHO)

Research needed to generate new evidence for global/regional recommendations



Research needed at country level to implement current WHO recommendations

Country process

- 1. Identify policy gaps in each country
- 2. Address gaps in evidence to guide policies
- 3. Design, validate, pilot new policies
- **4. Implement new policies** and strategies

Regional agenda

Identification of policy gaps

PAHO, Malaria TAG, partners, Plan of Action,



- Standardization of protocols
- Development of tools
- Financing / Mobilization
- Technical support network
- South south cooperation
 - Capacity building
 - Exchange of information
 - Exchange of experiences



Country process

1. Identify policy gaps in each country


2. Address gaps in evidence to guide policies

3. Design, validate, pilot new policies

4. Implement new policies and strategies

Partnership

Malaria Technical Advisory Group (Malaria TAG)






Plan of Action for **Malaria Elimination** 2021-2025

Partnership







University of California San Francisco



















malaria



















